InsiderSignalSign in
← Insider buys

Patrick J. Haley has sold EXEL and made no open-market buys since Mar 2017

EVP, Commercial at Exelixis, Inc.

SEC CIK 0001692954 · Filings on SEC.gov ↗

$0Bought
$25.3MSold
NoneLast buy

Every filing

43 filings since Mar 2017, newest first

EXELSell

Exelixis, Inc.

EVP, Commercial

$1.6M−8.0%May 22
EXELSell

Exelixis, Inc.

EVP, Commercial

$3.0M−15.0%Feb 18
EXELSell

Exelixis, Inc.

EVP, Commercial

$3.0M−16.0%Nov 24
EXELSell

Exelixis, Inc.

EVP, Commercial

$353K−3.0%Nov 26
EXELSell

Exelixis, Inc.

EVP, Commercial

$1.4M−11.0%Nov 19
EXELSell

Exelixis, Inc.

EVP, Commercial

$357K−4.0%Aug 9
EXELSell

Exelixis, Inc.

EVP, Commercial

$1.0M−10.0%Feb 27
EXELSell

Exelixis, Inc.

EVP, Commercial

$1.5M−16.0%Dec 14
EXELSell

Exelixis, Inc.

EVP, Commercial

$632K−9.0%Aug 7
EXELSell

Exelixis, Inc.

EVP, Commercial

$434K−8.0%Feb 8
EXELSell

Exelixis, Inc.

EVP, Commercial

$718K−12.0%Sep 14
EXELSell

Exelixis, Inc.

EVP, Commercial

$343K−6.0%Jun 1
EXELSell

Exelixis, Inc.

EVP, Commercial

$454K−6.0%Apr 4
EXELSell

Exelixis, Inc.

EVP, Commercial

$610K−12.0%Feb 28
EXELSell

Exelixis, Inc.

EVP, Commercial

$1.1M−18.0%Feb 4
EXELSell

Exelixis, Inc.

EVP, Commercial

$297K−6.0%Nov 26
EXELSell

Exelixis, Inc.

EVP, Commercial

$509K−7.0%Sep 17
EXELSell

Exelixis, Inc.

EVP, Commercial

$361K−4.0%May 18
EXELSell

Exelixis, Inc.

EVP, Commercial

$192K−2.0%Apr 28
EXELSell

Exelixis, Inc.

EVP, Commercial

$971K−14.0%Feb 17
EXELSell

Exelixis, Inc.

EVP, Commercial

$122K−3.0%Sep 23
EXELSell

Exelixis, Inc.

EVP, Commercial

$80K−2.0%Jul 22
EXELSell

Exelixis, Inc.

EVP, Commercial

$79K−2.0%May 22
EXELSell

Exelixis, Inc.

EVP, Commercial

$553K−12.0%May 8
EXELSell

Exelixis, Inc.

EVP, Commercial

$130K−3.0%Apr 24
EXELSell

Exelixis, Inc.

EVP, Commercial

$120K−3.0%Apr 22
EXELSell

Exelixis, Inc.

EVP, Commercial

$66K−3.0%Mar 20
EXELSell

Exelixis, Inc.

EVP, Commercial

$110K−3.0%Feb 21
EXELSell

Exelixis, Inc.

SVP, Commercial

$501K−17.0%Aug 8
EXELSell

Exelixis, Inc.

SVP, Commercial

$63K−2.0%Mar 27
EXELSell

Exelixis, Inc.

SVP, Commercial

$50K−2.0%Mar 15
EXELSell

Exelixis, Inc.

SVP, Commercial

$95K−3.0%Feb 27
EXELSell

Exelixis, Inc.

SVP, Commercial

$72K−2.0%Jan 11
EXELSell

Exelixis, Inc.

SVP, Commercial

$202K−7.0%Jan 9
EXELSell

Exelixis, Inc.

SVP, Commercial

$160K−6.0%Jan 4
EXELSell

Exelixis, Inc.

SVP, Commercial

$346K−13.0%Nov 9
EXELSell

Exelixis, Inc.

SVP, Commercial

$49K−1.0%Aug 8
EXELSell

Exelixis, Inc.

SVP, Commercial

$79K−2.0%May 18
EXELSell

Exelixis, Inc.

SVP, Commercial

$611K−14.0%May 7
EXELSell

Exelixis, Inc.

SVP, Commercial

$1.2M−23.0%Mar 2
EXELSell

Exelixis, Inc.

SVP, Commercial

$1.7M−45.0%Sep 15
EXELSell

Exelixis, Inc.

SVP, Commercial

$92K−4.0%Jun 1
EXELSell

Exelixis, Inc.

SVP, Commercial

$58K−2.0%Mar 7
About Patrick J. Haley

Patrick J. Haley is Executive Vice President, Commercial at Exelixis, Inc. (EXEL), a role he has held since February 2020, after joining the company in 2010 and advancing through progressively senior commercial positions including SVP, Commercial, VP, Commercial, and various marketing and sales director roles.( Under his leadership, Exelixis' net product revenues grew significantly from $1,077.3 million in 2021 to $1,809.4 million in 2024, driven by strong commercialization of the cabozantinib franchise, including CABOMETYX launches.(

Haley, age 49, holds an MBA from the University of Michigan (Ross School of Business) and a BA from Duke University.( His prior experience includes oncology brand management at Genentech (2007–2010), sales and marketing roles at Amgen (2003–2007), and analyst positions at PwC Securities, Lehman Brothers, and Accenture (1998–2001).( Currently, he serves as a Director at NetraMark Holdings, Inc. since October 2024.( Recently, on February 17, 2026, Haley sold 67,814 shares of EXEL stock for approximately $2.95 million.(

Written by Perplexity from public sources.

Filings come from SEC EDGAR. Not investment advice.